- Home
- TALO vs OGN Comparison
TALO vs OGN Comparison
Compare TALO & OGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TALO | OGN |
|---|---|---|
| Founded | 2011 | 1923 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.8B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | TALO | OGN |
|---|---|---|
| Price | $11.82 | $8.10 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 5 | 5 |
| Target Price | ★ $14.70 | $14.10 |
| AVG Volume (30 Days) | 1.9M | ★ 6.9M |
| Earning Date | 02-24-2026 | 02-12-2026 |
| Dividend Yield | N/A | ★ 0.98% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 1.91 |
| Revenue | $1,872,554,000.00 | ★ $6,301,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $4.29 |
| Revenue Growth | ★ 0.06 | N/A |
| 52 Week Low | $6.23 | $6.18 |
| 52 Week High | $12.37 | $17.23 |
Technical Indicators
Market Signals| Indicator | TALO | OGN |
|---|---|---|
| Relative Strength Index (RSI) | 56.60 | 43.82 |
| Support Level | $11.41 | $8.17 |
| Resistance Level | $12.37 | $8.53 |
| Average True Range (ATR) | 0.47 | 0.43 |
| MACD | 0.04 | -0.15 |
| Stochastic Oscillator | 58.33 | 1.85 |
Price Performance
Historical ComparisonAbout TALO Talos Energy Inc.
Talos Energy Inc is an independent oil and gas company predominantly involved in offshore exploration and production. The company has operations in the United States, the Gulf of Mexico, and offshore Mexico. The company's operating segments are; exploration and production of oil, natural gas and NGLs, and the CCS segment. The revenue is generated from the sale of oil, natural gas, and NGL quantities sold to purchasers.
About OGN Organon & Co.
Organon & Co is a science-based pharmaceutical company that develops and delivers health solutions through a portfolio of prescription therapies within women's health, biosimilars, and established brands. The Company's operations include the following product portfolio: Women's health, Biosimilars and Established medicines. Geographically, it derives a majority of its revenue from Europe and Canada followed by the United States and then Asia Pacific and Japan. The company generates the majority of its revenue from the Established Brands product portfolio.